The epidemiology of R. equi in humans, particularly its impact on immunocompromised individuals like AIDS patients or transplant recipients, has garnered attention, especially in the context of the COVID-19 pandemic. This bacterium is known to cause pneumonia and various infections in susceptible human populations. Additionally, R. equi is capable of infecting animals, including horses, pigs, and wild boars.
The global prevalence of Rhodococcus equi infection in humansremains uncertain, with estimates ranging from 0.06% to 0.3% of all pneumonia cases in AIDS patients. However, variations in prevalence are anticipated due to factors such as geographical location, the availability of diagnostic tools, and exposure to environmental sources of the bacterium.
Studies have reported diverse incidences, highlighting the complexity of its epidemiology. For instance, one study found an incidence of 0.8% in lung transplant recipients, while another reported a 0.2% incidence in preterm infants with respiratory distress. Notably, localized outbreaks have occurred, such as one in a French farm where seven workers contracted Rhodococcus equi from contact with infected pigs.
Kingdom: Bacteria
Phylum: Actinomycetota
Class: Actinomycetia
Order: Mycobacteriales
Family: Nocardiaceae
Genus:Rhodococcus
Species:R. equi
Rhodococcus equi is a gram-positive coccobacillus bacterium exhibiting an obligately aerobic lifestyle. Its non-motile and non-spore-forming nature characterizes it. A distinctive feature of R. equi is its facultative intracellular behavior, allowing it to survive and multiply within host cells, notably macrophages.
The morphology of R. equi is dynamic, with variations from bacillary to coccoid forms depending on growth conditions. In the early stages of growth in the culture broth, the bacteria appear rod-shaped, transitioning to a coccoid morphology after a day of growth in liquid media or on blood agar. The size of R. equi cells is variable, ranging from 0.5 to 5 μm in diameter.
R. equi isolates from pneumonic foals and various animals, including humans, cattle, and pigs, commonly harbor a substantial plasmid (80–90 kb). This plasmid is of paramount importance for R. equi‘s virulence and ability to survive within host cells. The plasmid encodes a surface protein known as virulence-associated protein A (VapA).
VapA plays a critical role in the evasion of the host immune response by interfering with the fusion of phagosomes and lysosomes. This interference prevents the degradation of R. equi by host enzymes and acids. Additionally, VapA induces the production of pro-inflammatory cytokines, like interleukin-1 beta and tumor necrosis factor-alpha, contributing to tissue damage and inflammation.
R. equi exhibits resistance to certain antibiotics due to specific genes. Among these, the gene aac(6′)-Ie-aph (2″)-Ia is noteworthy as it encodes an aminoglycoside-modifying enzyme, conferring resistance to aminoglycosides like gentamicin.
Another virulence factor is Perfringolysin O (PFO), a secreted toxin capable of forming pores on the host cell membrane, resulting in cell death and inflammation. The type strain of R. equi is NCTC 1621, with alternative designations including ATCC 25729 and NRRL B-16538. These identifiers are crucial for accurate referencing and standardization in research and diagnostic contexts.
The pathogenesis of R. equi involves several vital mechanisms that contribute to its ability to cause infections in humans. The primary route of transmission is through the inhalation of aerosolized dust particles containing R. equi, leading to the development of pneumonia, which is the most common manifestation of infection.
This respiratory route is a significant factor in the transmission dynamics of the bacterium, particularly in environments where aerosolized particles are prevalent. Once inhaled, Rhodococcus demonstrates a remarkable ability to survive and multiply within macrophages, which are immune cells responsible for eliminating bacteria.
The bacterium can evade the standard bactericidal mechanisms by escaping from the phagosome—a compartment designed for bacterial degradation—and replicate in the cytoplasm. This intracellular survival strategy allows R. equi to avoid detection & destruction by the host immune system, contributing to its persistence and the establishment of infection.The dissemination of R. equi from the lungs to other organs represents a critical aspect of its pathogenesis.
Organs such as the brain, spleen, liver, bone, skin, and lymph nodes can become sites of infection. Extrapulmonary infections, more prevalent in individuals with advanced immunodeficiency, such as those with HIV infection, underscore the systemic impact of R. equi. Notably, recent studies have suggested a potential association between R. equi infection and an increased risk of severe outcomes in COVID-19, including hospitalization, intensive care unit admission, or death.
The defense mechanism of the human host against Rhodococcus equi is a sophisticated interplay between innate and adaptive immunity. Innate immunity constitutes the first line of defense and involves physical barriers along with molecular components, such as natural killer cells, macrophages, neutrophils, complement, and cytokines.
These elements collectively recognize and attempt to eliminate R. equi through processes like phagocytosis, oxidative burst, nitric oxide production, autophagy, and inflammasome activation.
However, R. equi possesses virulence factors, notably virulence-associated protein A (VapA), which hinders phagosome-lysosome fusion, evading degradation by host enzymes and acids. Additionally, R. equi can manipulate the host’s immune sensing, potentially impairing the antibacterial activity of macrophages and facilitating its survival.
Adaptive immunity, the second line of defense, engages antigen-specific lymphocytes such as T cells and B cells, along with their products like antibodies and cytokines. This arm of the immune system provides protection. It establishes memory against R. equi through mechanisms like antibody-mediated opsonization, complement-mediated lysis, antibody-dependent cellular cytotoxicity, and T-cell-mediated cytotoxicity.
Yet, R. equi employs capsular polysaccharide (CPS) to counteract these mechanisms. CPS inhibits the production of nitric oxide and reactive oxygen species by macrophages. At the same time, LPS activates toll-like receptor 4 (TLR4) and the nuclear factor kappa B (NF-κB) pathway, regulating genes involved in immunity and inflammation.
Immunocompromised hosts, including those with HIV-AIDS, transplant recipients, cancer patients, or preterm infants, are particularly vulnerable to R. equi infection due to weakened or impaired immune responses.
For instance, HIV-AIDS patients exhibit reduced CD4+ T cell numbers and functionality, critical for immune cell activation. Transplant recipients face a suppressed immune system from immunosuppressive drugs, impairing various immune cell functions.
Cancer patients experience compromised immunity due to malignancy or cancer treatment, affecting the production and function of critical immune cells. Preterm infants with an underdeveloped immune system lack the full maturation of innate and adaptive immune components, making them susceptible to R. equi infection.
Rhodococcus equi infections commonly present as pneumonia, with symptoms characterized by a subacute onset, leading to high fever, cough, fatigue, chest pain, and weight loss. Radiographic examinations often reveal upper lobe cavitation, occasionally accompanied by necrosis, contributing to the clinical picture. This pulmonary manifestation is a hallmark of rhodococcal infections and is a primary concern in affected individuals.
Beyond the respiratory system, R. equi can cause extrapulmonary infections, which may or may not coincide with pneumonia. These diverse extrapulmonary manifestations include pericarditis, mastitis, empyema, mediastinal and intra-abdominal lymphadenopathy, brain, and psoas abscesses, as well as osteomyelitis and spondylodiscitis.
Notably, these extrapulmonary infections are more prevalent in immunocompromised patients, such as individuals with HIV-AIDS or those who have undergone transplantation, highlighting the opportunistic nature of Rhodococcus equi.
Bacteremia is a frequent occurrence in R. equi infections, heightening the risk of disseminated infection and associated complications. In particular, sepsis can manifest as a rare but severe complication, especially in preterm infants experiencing respiratory distress. The onset of sepsis can be life-threatening if not promptly and effectively addressed.
Culture test: Culture serves as the gold standard for diagnosing R. equi infections, allowing the isolation and identification of the bacterium from clinical specimens such as sputum, blood, or tissue. The morphology of R. equi varies from bacillary to coccoid depending on growth conditions, with colonies appearing shiny, smooth, and non-hemolytic on blood agar. However, culture has limitations, including the need for special media, slow growth, and potential contamination.
PCR: Polymerase Chain Reaction is a molecular technique detecting specific DNA sequences of R. equi in clinical specimens. It offers advantages over culture, such as faster turnaround time, higher sensitivity, and specificity. PCR can differentiate between virulent and avirulent strains based on detecting virulence-associated protein (Vap) genes. Drawbacks include the need for specialized equipment, the risk of contamination, and the inability to determine antibiotic susceptibility.
Serology: Serology, an immunological technique, measures the host’s antibody response to R. equi infection. It aids in diagnosing past or current infections, monitoring treatment response, and assessing the host’s immune status. Serology methods include ELISA, immunodiffusion, or complement fixation. Although convenient and cost-effective, serology has limitations such as low sensitivity and specificity, cross-reactivity, and result interpretation challenges.
Imaging: Imaging, a radiological technique, visualizes lesions caused by R. equi infections in lungs or other organs. Methods include chest radiography, ultrasonography, CT, or MRI. Imaging provides valuable information on lesion location, size, number, and potential complications. While non-invasive and useful for treatment monitoring, imaging drawbacks include high cost, radiation exposure, and lack of specificity.
Regularly washing hands with soap and water is crucial to minimize the risk of R. equi infection. This practice becomes especially important after handling animals or their products since the bacterium can be present in soil and animal feces.
To reduce the risk of Rhodococcus equi exposure, it is crucial to avoid close contact with infected animals, particularly those displaying symptoms of infection. If working with animals is unavoidable, protective measures such as wearing gloves, masks, and appropriate clothing should be implemented to minimize the risk of transmission.
The epidemiology of R. equi in humans, particularly its impact on immunocompromised individuals like AIDS patients or transplant recipients, has garnered attention, especially in the context of the COVID-19 pandemic. This bacterium is known to cause pneumonia and various infections in susceptible human populations. Additionally, R. equi is capable of infecting animals, including horses, pigs, and wild boars.
The global prevalence of Rhodococcus equi infection in humansremains uncertain, with estimates ranging from 0.06% to 0.3% of all pneumonia cases in AIDS patients. However, variations in prevalence are anticipated due to factors such as geographical location, the availability of diagnostic tools, and exposure to environmental sources of the bacterium.
Studies have reported diverse incidences, highlighting the complexity of its epidemiology. For instance, one study found an incidence of 0.8% in lung transplant recipients, while another reported a 0.2% incidence in preterm infants with respiratory distress. Notably, localized outbreaks have occurred, such as one in a French farm where seven workers contracted Rhodococcus equi from contact with infected pigs.
Kingdom: Bacteria
Phylum: Actinomycetota
Class: Actinomycetia
Order: Mycobacteriales
Family: Nocardiaceae
Genus:Rhodococcus
Species:R. equi
Rhodococcus equi is a gram-positive coccobacillus bacterium exhibiting an obligately aerobic lifestyle. Its non-motile and non-spore-forming nature characterizes it. A distinctive feature of R. equi is its facultative intracellular behavior, allowing it to survive and multiply within host cells, notably macrophages.
The morphology of R. equi is dynamic, with variations from bacillary to coccoid forms depending on growth conditions. In the early stages of growth in the culture broth, the bacteria appear rod-shaped, transitioning to a coccoid morphology after a day of growth in liquid media or on blood agar. The size of R. equi cells is variable, ranging from 0.5 to 5 μm in diameter.
R. equi isolates from pneumonic foals and various animals, including humans, cattle, and pigs, commonly harbor a substantial plasmid (80–90 kb). This plasmid is of paramount importance for R. equi‘s virulence and ability to survive within host cells. The plasmid encodes a surface protein known as virulence-associated protein A (VapA).
VapA plays a critical role in the evasion of the host immune response by interfering with the fusion of phagosomes and lysosomes. This interference prevents the degradation of R. equi by host enzymes and acids. Additionally, VapA induces the production of pro-inflammatory cytokines, like interleukin-1 beta and tumor necrosis factor-alpha, contributing to tissue damage and inflammation.
R. equi exhibits resistance to certain antibiotics due to specific genes. Among these, the gene aac(6′)-Ie-aph (2″)-Ia is noteworthy as it encodes an aminoglycoside-modifying enzyme, conferring resistance to aminoglycosides like gentamicin.
Another virulence factor is Perfringolysin O (PFO), a secreted toxin capable of forming pores on the host cell membrane, resulting in cell death and inflammation. The type strain of R. equi is NCTC 1621, with alternative designations including ATCC 25729 and NRRL B-16538. These identifiers are crucial for accurate referencing and standardization in research and diagnostic contexts.
The pathogenesis of R. equi involves several vital mechanisms that contribute to its ability to cause infections in humans. The primary route of transmission is through the inhalation of aerosolized dust particles containing R. equi, leading to the development of pneumonia, which is the most common manifestation of infection.
This respiratory route is a significant factor in the transmission dynamics of the bacterium, particularly in environments where aerosolized particles are prevalent. Once inhaled, Rhodococcus demonstrates a remarkable ability to survive and multiply within macrophages, which are immune cells responsible for eliminating bacteria.
The bacterium can evade the standard bactericidal mechanisms by escaping from the phagosome—a compartment designed for bacterial degradation—and replicate in the cytoplasm. This intracellular survival strategy allows R. equi to avoid detection & destruction by the host immune system, contributing to its persistence and the establishment of infection.The dissemination of R. equi from the lungs to other organs represents a critical aspect of its pathogenesis.
Organs such as the brain, spleen, liver, bone, skin, and lymph nodes can become sites of infection. Extrapulmonary infections, more prevalent in individuals with advanced immunodeficiency, such as those with HIV infection, underscore the systemic impact of R. equi. Notably, recent studies have suggested a potential association between R. equi infection and an increased risk of severe outcomes in COVID-19, including hospitalization, intensive care unit admission, or death.
The defense mechanism of the human host against Rhodococcus equi is a sophisticated interplay between innate and adaptive immunity. Innate immunity constitutes the first line of defense and involves physical barriers along with molecular components, such as natural killer cells, macrophages, neutrophils, complement, and cytokines.
These elements collectively recognize and attempt to eliminate R. equi through processes like phagocytosis, oxidative burst, nitric oxide production, autophagy, and inflammasome activation.
However, R. equi possesses virulence factors, notably virulence-associated protein A (VapA), which hinders phagosome-lysosome fusion, evading degradation by host enzymes and acids. Additionally, R. equi can manipulate the host’s immune sensing, potentially impairing the antibacterial activity of macrophages and facilitating its survival.
Adaptive immunity, the second line of defense, engages antigen-specific lymphocytes such as T cells and B cells, along with their products like antibodies and cytokines. This arm of the immune system provides protection. It establishes memory against R. equi through mechanisms like antibody-mediated opsonization, complement-mediated lysis, antibody-dependent cellular cytotoxicity, and T-cell-mediated cytotoxicity.
Yet, R. equi employs capsular polysaccharide (CPS) to counteract these mechanisms. CPS inhibits the production of nitric oxide and reactive oxygen species by macrophages. At the same time, LPS activates toll-like receptor 4 (TLR4) and the nuclear factor kappa B (NF-κB) pathway, regulating genes involved in immunity and inflammation.
Immunocompromised hosts, including those with HIV-AIDS, transplant recipients, cancer patients, or preterm infants, are particularly vulnerable to R. equi infection due to weakened or impaired immune responses.
For instance, HIV-AIDS patients exhibit reduced CD4+ T cell numbers and functionality, critical for immune cell activation. Transplant recipients face a suppressed immune system from immunosuppressive drugs, impairing various immune cell functions.
Cancer patients experience compromised immunity due to malignancy or cancer treatment, affecting the production and function of critical immune cells. Preterm infants with an underdeveloped immune system lack the full maturation of innate and adaptive immune components, making them susceptible to R. equi infection.
Rhodococcus equi infections commonly present as pneumonia, with symptoms characterized by a subacute onset, leading to high fever, cough, fatigue, chest pain, and weight loss. Radiographic examinations often reveal upper lobe cavitation, occasionally accompanied by necrosis, contributing to the clinical picture. This pulmonary manifestation is a hallmark of rhodococcal infections and is a primary concern in affected individuals.
Beyond the respiratory system, R. equi can cause extrapulmonary infections, which may or may not coincide with pneumonia. These diverse extrapulmonary manifestations include pericarditis, mastitis, empyema, mediastinal and intra-abdominal lymphadenopathy, brain, and psoas abscesses, as well as osteomyelitis and spondylodiscitis.
Notably, these extrapulmonary infections are more prevalent in immunocompromised patients, such as individuals with HIV-AIDS or those who have undergone transplantation, highlighting the opportunistic nature of Rhodococcus equi.
Bacteremia is a frequent occurrence in R. equi infections, heightening the risk of disseminated infection and associated complications. In particular, sepsis can manifest as a rare but severe complication, especially in preterm infants experiencing respiratory distress. The onset of sepsis can be life-threatening if not promptly and effectively addressed.
Culture test: Culture serves as the gold standard for diagnosing R. equi infections, allowing the isolation and identification of the bacterium from clinical specimens such as sputum, blood, or tissue. The morphology of R. equi varies from bacillary to coccoid depending on growth conditions, with colonies appearing shiny, smooth, and non-hemolytic on blood agar. However, culture has limitations, including the need for special media, slow growth, and potential contamination.
PCR: Polymerase Chain Reaction is a molecular technique detecting specific DNA sequences of R. equi in clinical specimens. It offers advantages over culture, such as faster turnaround time, higher sensitivity, and specificity. PCR can differentiate between virulent and avirulent strains based on detecting virulence-associated protein (Vap) genes. Drawbacks include the need for specialized equipment, the risk of contamination, and the inability to determine antibiotic susceptibility.
Serology: Serology, an immunological technique, measures the host’s antibody response to R. equi infection. It aids in diagnosing past or current infections, monitoring treatment response, and assessing the host’s immune status. Serology methods include ELISA, immunodiffusion, or complement fixation. Although convenient and cost-effective, serology has limitations such as low sensitivity and specificity, cross-reactivity, and result interpretation challenges.
Imaging: Imaging, a radiological technique, visualizes lesions caused by R. equi infections in lungs or other organs. Methods include chest radiography, ultrasonography, CT, or MRI. Imaging provides valuable information on lesion location, size, number, and potential complications. While non-invasive and useful for treatment monitoring, imaging drawbacks include high cost, radiation exposure, and lack of specificity.
Regularly washing hands with soap and water is crucial to minimize the risk of R. equi infection. This practice becomes especially important after handling animals or their products since the bacterium can be present in soil and animal feces.
To reduce the risk of Rhodococcus equi exposure, it is crucial to avoid close contact with infected animals, particularly those displaying symptoms of infection. If working with animals is unavoidable, protective measures such as wearing gloves, masks, and appropriate clothing should be implemented to minimize the risk of transmission.
The epidemiology of R. equi in humans, particularly its impact on immunocompromised individuals like AIDS patients or transplant recipients, has garnered attention, especially in the context of the COVID-19 pandemic. This bacterium is known to cause pneumonia and various infections in susceptible human populations. Additionally, R. equi is capable of infecting animals, including horses, pigs, and wild boars.
The global prevalence of Rhodococcus equi infection in humansremains uncertain, with estimates ranging from 0.06% to 0.3% of all pneumonia cases in AIDS patients. However, variations in prevalence are anticipated due to factors such as geographical location, the availability of diagnostic tools, and exposure to environmental sources of the bacterium.
Studies have reported diverse incidences, highlighting the complexity of its epidemiology. For instance, one study found an incidence of 0.8% in lung transplant recipients, while another reported a 0.2% incidence in preterm infants with respiratory distress. Notably, localized outbreaks have occurred, such as one in a French farm where seven workers contracted Rhodococcus equi from contact with infected pigs.
Kingdom: Bacteria
Phylum: Actinomycetota
Class: Actinomycetia
Order: Mycobacteriales
Family: Nocardiaceae
Genus:Rhodococcus
Species:R. equi
Rhodococcus equi is a gram-positive coccobacillus bacterium exhibiting an obligately aerobic lifestyle. Its non-motile and non-spore-forming nature characterizes it. A distinctive feature of R. equi is its facultative intracellular behavior, allowing it to survive and multiply within host cells, notably macrophages.
The morphology of R. equi is dynamic, with variations from bacillary to coccoid forms depending on growth conditions. In the early stages of growth in the culture broth, the bacteria appear rod-shaped, transitioning to a coccoid morphology after a day of growth in liquid media or on blood agar. The size of R. equi cells is variable, ranging from 0.5 to 5 μm in diameter.
R. equi isolates from pneumonic foals and various animals, including humans, cattle, and pigs, commonly harbor a substantial plasmid (80–90 kb). This plasmid is of paramount importance for R. equi‘s virulence and ability to survive within host cells. The plasmid encodes a surface protein known as virulence-associated protein A (VapA).
VapA plays a critical role in the evasion of the host immune response by interfering with the fusion of phagosomes and lysosomes. This interference prevents the degradation of R. equi by host enzymes and acids. Additionally, VapA induces the production of pro-inflammatory cytokines, like interleukin-1 beta and tumor necrosis factor-alpha, contributing to tissue damage and inflammation.
R. equi exhibits resistance to certain antibiotics due to specific genes. Among these, the gene aac(6′)-Ie-aph (2″)-Ia is noteworthy as it encodes an aminoglycoside-modifying enzyme, conferring resistance to aminoglycosides like gentamicin.
Another virulence factor is Perfringolysin O (PFO), a secreted toxin capable of forming pores on the host cell membrane, resulting in cell death and inflammation. The type strain of R. equi is NCTC 1621, with alternative designations including ATCC 25729 and NRRL B-16538. These identifiers are crucial for accurate referencing and standardization in research and diagnostic contexts.
The pathogenesis of R. equi involves several vital mechanisms that contribute to its ability to cause infections in humans. The primary route of transmission is through the inhalation of aerosolized dust particles containing R. equi, leading to the development of pneumonia, which is the most common manifestation of infection.
This respiratory route is a significant factor in the transmission dynamics of the bacterium, particularly in environments where aerosolized particles are prevalent. Once inhaled, Rhodococcus demonstrates a remarkable ability to survive and multiply within macrophages, which are immune cells responsible for eliminating bacteria.
The bacterium can evade the standard bactericidal mechanisms by escaping from the phagosome—a compartment designed for bacterial degradation—and replicate in the cytoplasm. This intracellular survival strategy allows R. equi to avoid detection & destruction by the host immune system, contributing to its persistence and the establishment of infection.The dissemination of R. equi from the lungs to other organs represents a critical aspect of its pathogenesis.
Organs such as the brain, spleen, liver, bone, skin, and lymph nodes can become sites of infection. Extrapulmonary infections, more prevalent in individuals with advanced immunodeficiency, such as those with HIV infection, underscore the systemic impact of R. equi. Notably, recent studies have suggested a potential association between R. equi infection and an increased risk of severe outcomes in COVID-19, including hospitalization, intensive care unit admission, or death.
The defense mechanism of the human host against Rhodococcus equi is a sophisticated interplay between innate and adaptive immunity. Innate immunity constitutes the first line of defense and involves physical barriers along with molecular components, such as natural killer cells, macrophages, neutrophils, complement, and cytokines.
These elements collectively recognize and attempt to eliminate R. equi through processes like phagocytosis, oxidative burst, nitric oxide production, autophagy, and inflammasome activation.
However, R. equi possesses virulence factors, notably virulence-associated protein A (VapA), which hinders phagosome-lysosome fusion, evading degradation by host enzymes and acids. Additionally, R. equi can manipulate the host’s immune sensing, potentially impairing the antibacterial activity of macrophages and facilitating its survival.
Adaptive immunity, the second line of defense, engages antigen-specific lymphocytes such as T cells and B cells, along with their products like antibodies and cytokines. This arm of the immune system provides protection. It establishes memory against R. equi through mechanisms like antibody-mediated opsonization, complement-mediated lysis, antibody-dependent cellular cytotoxicity, and T-cell-mediated cytotoxicity.
Yet, R. equi employs capsular polysaccharide (CPS) to counteract these mechanisms. CPS inhibits the production of nitric oxide and reactive oxygen species by macrophages. At the same time, LPS activates toll-like receptor 4 (TLR4) and the nuclear factor kappa B (NF-κB) pathway, regulating genes involved in immunity and inflammation.
Immunocompromised hosts, including those with HIV-AIDS, transplant recipients, cancer patients, or preterm infants, are particularly vulnerable to R. equi infection due to weakened or impaired immune responses.
For instance, HIV-AIDS patients exhibit reduced CD4+ T cell numbers and functionality, critical for immune cell activation. Transplant recipients face a suppressed immune system from immunosuppressive drugs, impairing various immune cell functions.
Cancer patients experience compromised immunity due to malignancy or cancer treatment, affecting the production and function of critical immune cells. Preterm infants with an underdeveloped immune system lack the full maturation of innate and adaptive immune components, making them susceptible to R. equi infection.
Rhodococcus equi infections commonly present as pneumonia, with symptoms characterized by a subacute onset, leading to high fever, cough, fatigue, chest pain, and weight loss. Radiographic examinations often reveal upper lobe cavitation, occasionally accompanied by necrosis, contributing to the clinical picture. This pulmonary manifestation is a hallmark of rhodococcal infections and is a primary concern in affected individuals.
Beyond the respiratory system, R. equi can cause extrapulmonary infections, which may or may not coincide with pneumonia. These diverse extrapulmonary manifestations include pericarditis, mastitis, empyema, mediastinal and intra-abdominal lymphadenopathy, brain, and psoas abscesses, as well as osteomyelitis and spondylodiscitis.
Notably, these extrapulmonary infections are more prevalent in immunocompromised patients, such as individuals with HIV-AIDS or those who have undergone transplantation, highlighting the opportunistic nature of Rhodococcus equi.
Bacteremia is a frequent occurrence in R. equi infections, heightening the risk of disseminated infection and associated complications. In particular, sepsis can manifest as a rare but severe complication, especially in preterm infants experiencing respiratory distress. The onset of sepsis can be life-threatening if not promptly and effectively addressed.
Culture test: Culture serves as the gold standard for diagnosing R. equi infections, allowing the isolation and identification of the bacterium from clinical specimens such as sputum, blood, or tissue. The morphology of R. equi varies from bacillary to coccoid depending on growth conditions, with colonies appearing shiny, smooth, and non-hemolytic on blood agar. However, culture has limitations, including the need for special media, slow growth, and potential contamination.
PCR: Polymerase Chain Reaction is a molecular technique detecting specific DNA sequences of R. equi in clinical specimens. It offers advantages over culture, such as faster turnaround time, higher sensitivity, and specificity. PCR can differentiate between virulent and avirulent strains based on detecting virulence-associated protein (Vap) genes. Drawbacks include the need for specialized equipment, the risk of contamination, and the inability to determine antibiotic susceptibility.
Serology: Serology, an immunological technique, measures the host’s antibody response to R. equi infection. It aids in diagnosing past or current infections, monitoring treatment response, and assessing the host’s immune status. Serology methods include ELISA, immunodiffusion, or complement fixation. Although convenient and cost-effective, serology has limitations such as low sensitivity and specificity, cross-reactivity, and result interpretation challenges.
Imaging: Imaging, a radiological technique, visualizes lesions caused by R. equi infections in lungs or other organs. Methods include chest radiography, ultrasonography, CT, or MRI. Imaging provides valuable information on lesion location, size, number, and potential complications. While non-invasive and useful for treatment monitoring, imaging drawbacks include high cost, radiation exposure, and lack of specificity.
Regularly washing hands with soap and water is crucial to minimize the risk of R. equi infection. This practice becomes especially important after handling animals or their products since the bacterium can be present in soil and animal feces.
To reduce the risk of Rhodococcus equi exposure, it is crucial to avoid close contact with infected animals, particularly those displaying symptoms of infection. If working with animals is unavoidable, protective measures such as wearing gloves, masks, and appropriate clothing should be implemented to minimize the risk of transmission.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
